SCHEMBL8221606

SCHEMBL8221606

CC(=O)[C@@H](NC(=O)c1ccccc1)C1CCCCC1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CCR1 P32246 1/20 0.56
CTSL P07711 5/20 0.53
CTSS P25774 4/20 0.53
CTSK P43235 4/20 0.53
CTSV O60911 3/20 0.53
KMT2A Q03164 3/20 0.50
CTSB P07858 2/20 0.50
MEN1 O00255 2/20 0.50
ALDH1A1 P00352 2/20 0.50
MAPK1 P28482 1/20 0.50
NPC1 O15118 2/20 0.49
RAB9A P51151 2/20 0.49
PLAU P00749 1/20 0.47
HPN P05981 1/20 0.47
MMP13 P45452 1/20 0.46
ENPP2 Q13822 1/20 0.45
LMNA P02545 1/20 0.45
KCNK3 O14649 1/20 0.45
KCNK9 Q9NPC2 1/20 0.45
MAPT P10636 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21274424 0.86 CCR1 (0.56) CCR1CTSLCTSSCTSKCTSV
SCHEMBL21274426 0.86 CCR1 (0.56) CCR1CTSLCTSSCTSKCTSV
SCHEMBL8013143 0.85 CCR1 (0.54) CCR1CTSLCTSSCTSKCTSV
SCHEMBL10072498 0.84 CCR1 (0.53) CCR1CTSLCTSSCTSKCTSV
SCHEMBL27666303 0.81 TAS1R3 (0.55) CCR1CTSLCTSSCTSKKMT2A
SCHEMBL27666301 0.81 TAS1R3 (0.55) CCR1CTSLCTSSCTSKKMT2A
SCHEMBL27337850 0.81 RAB9A (0.54) CCR1CTSLCTSSCTSKCTSV
SCHEMBL5598241 0.80 RAB9A (0.53) CCR1CTSLCTSSCTSKCTSV
SCHEMBL6171268 0.80 RAB9A (0.53) CCR1CTSLCTSSCTSKCTSV
SCHEMBL7761517 0.80 RAB9A (0.53) CCR1CTSLCTSSCTSKCTSV

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8361958-B2 Oximyl HCV serine protease inhibitors ENANTA PHARMACEUTICALS, INC. (US) 2013-01-29 US disclosed
US-8101567-B2 Heteroaryl-containing tripeptide HCV serine protease inhibitors ENANTA PHARMACEUTICALS, INC. (US) 2012-01-24 US disclosed
US-20090202485-A1 HETEROARYL-CONTAINING TRIPEPTIDE HCV SERINE PROTEASE INHIBITORS ENANTA PHARMACEUTICALS, INC. 2009-08-13 US disclosed
WO-2007146695-A1 ACYCLIC OXIMYL HEPATITIS C PROTEASE INHIBITORS ENANTA PHARMACEUTICALS, INC. (US) 2007-12-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090202485-A1 HETEROARYL-CONTAINING TRIPEPTIDE HCV SERINE PROTEASE INHIBITORS PRSS1, CTSC, SPINT2 CCR1 816/4885CTSL 33/4885CTSS 66/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.